![Mark J. Zoller](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark J. Zoller
Geen lopende functies
Profiel
Mark J.
Zoller joined Senomyx, Inc. in March 2000 as Vice President of Research.
He became Senior Vice President of Research and Chief Scientific Officer for Senomyx in June 2001.
From May 1992 to December 1999, Dr. Zoller held various scientific management positions at ARIAD Pharmaceuticals, including Senior Vice President of Genomics and Scientific Director of the Hoechst-ARIAD Genomics Center.
He received a BA degree in Chemistry from Pomona College and a PhD degree in Chemistry from the University of California, San Diego.
Eerdere bekende functies van Mark J. Zoller
Bedrijven | Functie | Einde |
---|---|---|
SENOMYX INC. | Hoofd Techniek/Wetenschap/O&O | 17-06-2009 |
ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-12-1999 |
Opleiding van Mark J. Zoller
Pomona College | Undergraduate Degree |
University of California San Diego | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Senomyx, Inc.
![]() Senomyx, Inc. Food: Specialty/CandyConsumer Non-Durables Senomyx, Inc. engages in the development and commercialization of flavor ingredients for the packaged food, beverage, and ingredient supply industries. It develops high intensity sweeteners, savory flavors, bitter taste blockers, and cooling agents. The company was founded by Paul A. Grayson, Lubert Stryer, Yon Chien Tsien, Denis Baylor, Harold McGee, and Charles Zuker on September 16, 1998 and is headquartered in San Diego, CA. | Consumer Non-Durables |
ARIAD Pharmaceuticals, Inc.
![]() ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |